ELVN Sale Disclosure
Collins Helen Louise · SEC Form 4 · Filed Aug 19, 2026
Sale
Calculated transaction value
$227.65K
Collins Helen Louise Chief Medical Officer
ELVN
Enliven Therapeutics
ELVN
Transaction date
Aug 17, 2026
Public filing date
Aug 19, 2026
Filing lag
Filed 2 days later
ELVN daily price context
Close on/before transaction
$59.53
Aug 17, 2026
Close before public filing
$60.07
Aug 18, 2026
Return since public filing
-16.36%
Through Sep 17, 2026
Source details
- Reported owner
- Not disclosed
- Source asset code
- Security
- Security
- Common Stock
- Quantity / price
- 3,900 shares @ $58.37
- SEC ownership
- Direct
- Transaction code
- S
- Form
- 4
- Filing identifier
- 0001701247-26-000012
Filing cohort
Transactions in this filing
Showing 4 of 4
Trades
4
Issuers
1
Estimated value
$305.33K
Buys / sales
0 / 2
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Enliven Therapeutics, Inc. ELVN | Exercise | Aug 17, 2026 | $12.4K |
| Enliven Therapeutics, Inc. ELVN Current | Sale | Aug 17, 2026 | $227.65K |
| Enliven Therapeutics, Inc. ELVN | Sale | Aug 17, 2026 | $65.28K |
| Enliven Therapeutics, Inc. ELVN | Exercise | Aug 17, 2026 | $0 |